SRF 78898

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK



In re

Chapter 11

ACORDA THERAPEUTICS, INC., et al.,

Debtors.

Case No. 24-22284 (DSJ)

Jointly Administered

Re: Docket Nos. 35 & 109

NOTICE TO CONTRACT PARTIES TO POTENTIALLY ASSUMED EXECUTORY CONTRACTS

YOU ARE RECEIVING THIS NOTICE BECAUSE YOU OR ONE OF YOUR AFFILIATES IS A COUNTERPARTY TO AN EXECUTORY CONTRACT WITH THE DEBTORS AS SET FORTH ON EXHIBIT A ATTACHED HERETO.

PLEASE TAKE NOTICE that on April 29, 2024, the United States Bankruptcy Court for the Southern District of New York (the "Court") entered the *Order* (A) Authorizing and Approving Bidding Procedures and Stalking Horse Bid Protections, (B) Scheduling an Auction and a Sale Hearing, (C) Approving the Form and Manner of Notice Thereof (D) Establishing Notice and Procedures for the Assumption and Assignment of Certain Executory Contracts, and (E) Granting Related Relief [Docket No. 109] (the "Bidding Procedures Order"), authorizing the Debtors to conduct an auction (the "Auction") to select the party to purchase the Acquired Assets. Any Auction will be governed by the bidding procedures approved pursuant to the Bidding Procedures Order (attached to the Bidding Procedures Order as Exhibit 1, the "Bidding Procedures").

PLEASE TAKE FURTHER NOTICE that, pursuant to the Bidding Procedures and the terms of any Successful Bid, the Debtors <u>may</u> assume and assign to the Successful Bidder the contract or agreement listed on <u>Exhibit A</u> (the "Cure Notice") to which you are a counterparty, upon approval of the Sale. The Debtors have conducted a review of their books and records and have determined that the cure cost for unpaid monetary

¹ The Debtors in these chapter 11 cases, along with the last four (4) digits of each Debtor's federal tax identification number, are: Acorda Therapeutics, Inc. (1168), Civitas Therapeutics, Inc. (2814), Biotie Therapies, LLC (2149), Biotie Therapies AG (N/A), Neuronex, Inc. (5094), and Acorda Therapeutics Limited (N/A). For the purposes of these chapter 11 cases, the address for the Debtors is: 2 Blue Hill Plaza, 3rd Floor, Pearl River, New York 10965.

² Capitalized terms used but not otherwise defined herein have the meanings ascribed to them in the Bidding Procedures or the Bidding Procedures Order, as applicable.

obligations under such Assigned Contracts is as set forth on **Exhibit A** attached hereto (the "Cure Costs").

PLEASE TAKE FURTHER NOTICE that if you disagree with the proposed Cure Costs, object to a proposed assignment to the Successful Bidder of any Assigned Contract, or object to the ability of the Successful Bidder to provide adequate assurance of future performance with respect to any Assigned Contract, your objection must: (i) be in writing; (ii) comply with the applicable provisions of the Bankruptcy Code, Bankruptcy Rules, Local Bankruptcy Rules, and any order governing the administration of these Chapter 11 Cases; (iii) state with specificity the nature of the objection and, if the objection pertains to the proposed Cure Costs, state the correct cure cost alleged to be owed to the objecting counterparty to any Assigned Contract, together with any applicable and appropriate documentation in support thereof; and (iv) be filed with the Court and served and actually received no later than May 20, 2024 at 4:00 p.m. (ET) (the "Contract Objection Deadline") by the Court and the following parties: (i) proposed counsel to the Debtors, Baker & McKenzie LLP (Attn: John R. Dodd (john.dodd@bakermckenzie.com), 1111 Brickell Avenue, 10th Floor, Miami, Florida 33131 and Blaire Cahn (blaire.cahn@bakermckenzie.com), 452 Fifth Avenue, New York, New York 10018); (ii) counsel to the Stalking Horse Bidder, Freshfields Bruckhaus Deringer US LP (Attn: Scott (scott.talmadge@freshfields.com) Ali Muffenbier D. Talmadge and (ali.muffenbier@freshfields.com), 3 World Trade Center, 175 Greenwich Street, New York, New York 10007); (iii) counsel for the U.S. Trustee (Attn: Tara Tiantian (Tara. Tiantian@usdoj.gov), Brian Masumoto (Brian. Masumoto@usdoj.gov), and Rachael E. Siegel (Rachael.E.Siegel@usdoj.gov), Alexander Hamilton Custom House, One Bowling Green, Suite 534, New York, New York 10004); (iv) counsel to the Ad Hoc Noteholder Group and DIP Lenders, King & Spalding LLP (Attn: Matthew Warren (mwarren@kslaw.com) and Lindsey Henrikson (lhenrikson@kslaw.com), 110 N Wacker Drive, Suite 3800, Chicago, Illinois 60606); (v) counsel to the DIP Administrative Agent, King & Spalding LLP (Attn: Geoffrey King (gking@kslaw.com), 110 N Wacker Drive, Suite 3800, Chicago, IL 60606); (vi) proposed counsel to the Creditors' Committee, McDermott Will & Emery LLP (Attn: Darren Azman (dazman@mwe.com), Kristin K. Going (kgoing@mwe.com), and Stacy Lutkus (salutkus@mwe.com), One Vanderbilt Avenue, New York, NY 10017); and (vii) any other party that has filed a notice of appearance in these Chapter 11 Cases.

PLEASE TAKE FURTHER NOTICE that if no objection to: (i) the Cure Costs, (ii) the proposed assignment and assumption of any Assigned Contract, or (iii) adequate assurance of the Successful Bidder's ability to perform is filed by the Contract Objection Deadline, then (a) you will be deemed to have stipulated that the Cure Cost as determined by the Debtors is correct, (b) you will be forever barred, estopped, and enjoined from asserting any additional cure cost under the proposed Assigned Contract, and (c) you will be forever barred, estopped, and enjoined from objecting to such proposed assignment to the Successful Bidder on the grounds that the Successful Bidder has not provided adequate assurance of future performance as of the closing date of the Sale.

PLEASE TAKE FURTHER NOTICE that any objection to the proposed assumption and assignment of an Assigned Contract or related Cure Costs in connection

with the Successful Bid that otherwise complies with these procedures yet remains unresolved as of the commencement of the Sale Hearing, shall be heard at a later date as may be fixed by the Court.

PLEASE THAT FURTHER NOTICE that, notwithstanding anything herein, the mere listing of any Assigned Contract on the Cure Notice does not require or guarantee that such Assigned Contract will be assumed by the Debtors at any time or assumed and assigned, and all rights of the Debtors and the Successful Bidder with respect to such executory contracts are reserved. Moreover, the Debtors explicitly reserves their rights, in their reasonable discretion, to seek to reject or assume each Assigned Contract pursuant to section 365(a) of the Bankruptcy Code and in accordance with the procedures allowing the Debtors and/or the Successful Bidder, as applicable, to designate any Assigned Contract as either rejected or assumed on a post-closing basis.

PLEASE TAKE FURTHER NOTICE that, nothing herein: (i) alters in any way the prepetition nature of the Assigned Contracts or the validity, priority, or amount of any claims of a counterparty to any Assigned Contract against the Debtors that may arise under such Assigned Contract, (ii) creates a postpetition contract or agreement, or (iii) elevates to administrative expense priority any claims of a counterparty to any Assigned Contract against the Debtors that may arise under such Assigned Contract.

PLEASE TAKE FURTHER NOTICE that you may obtain additional information concerning the above-captioned Chapter 11 Cases at the website maintained in these Chapter 11 Cases at https://cases.ra.kroll.com/Acorda.

PLEASE TAKE FURTHER NOTICE that questions regarding any proposed assumption and assignment of an Assigned Contract or related Cure Costs in connection with the Successful Bid may be directed to proposed counsel to the Debtors, Baker & McKenzie LLP via e-mail at john.dodd@bakermckenzie.com and blaire.cahn@bakermckenzie.com, and proposed counsel to the Creditors' Committee, McDermott Will & Emery LLP, via e-mail at dazman@mwe.com, kgoing@mwe.com, and salutkus@mwe.com.

[Remainder of page intentionally left blank]

Dated: May 1, 2024

/s/ John R. Dodd

John R. Dodd (admitted pro hac vice) **BAKER & McKENZIE LLP**1111 Brickell Avenue, 10th Floor

Miami, FL 33131

Telephone: 305-789-8900 Facsimile: 305-789-8953

Email: john.dodd@bakermckenzie.com

and

Blaire Cahn

BAKER & McKENZIE LLP

452 Fifth Avenue
New York, NY 10018
Telephone: 212-626-4100
Facsimile: 212-310-1600

Email: blaire.cahn@bakermckenzie.com

Proposed Counsel for the Debtors and Debtors-in-Possession

Exhibit A

Cure Notice

No.	Contract	Counter Party(s)	Cure Amount (\$)
1.	Pre-Launch Agreement, dated as of December 15, 2021, by and between Acorda Therapeutics, Inc. and RIS RX.	RIS RX	-
2.	First Amendment to the Master Patient Support Hub Services Agreement, dated as of September 1, 2022, by and between Acorda Therapeutics, Inc. and RIS RX.	RIS RX	-
3.	Master Patient Support Hub Services Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and RIS RX	RIS RX	\$54,780.50
4.	First Amendment to Adverse Event and Product Complaint Reporting Agreement, dated as of August 30, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
5.	First Amendment to the Master Direct Product Purchase and Dispensing Agreement, dated as of September 1, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
6.	Adverse Event and Product Complaint Reporting Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
7.	Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	\$25,285.11

No.	Contract	Counter Party(s)	Cure Amount (\$)
8.	Second Amendment to the Master Patient Support Hub Services Agreement, dated as of November 18, 2022, by and	RIS RX	-
	between RIS Rx and Acorda Therapeutics, Inc.	12.	
9.	Third Amendment to the Master Patient Support Hub Services Agreement, dated as of March 8, 2023, by and between RIS Rx and Acorda Therapeutics, Inc.	RIS RX	- Clarect grown or a constant of the constant
10.	Fourth Amendment to the Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2022, by and between SterlingRx, Inc. and Acorda Therapeutics, Inc.	SterlingRX	
11.	Fourth Amendment to the Pharmacy Services Agreement, dated as of February 15, 2022, by and between SterlingRx, Inc. and Acorda Therapeutics, Inc.	SterlingRX	and Allegarian
12.	Project Addendum #1 to the Master Market Access Service Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC	Covance Specialty Pharmacy LLC	And all meaning a parties of a second control of the second contro
13.	McKesson Corporation Core Distribution Agreement, dated as of October 8, 2007, by and between Acorda Therapeutics, Inc. and the McKesson Corporation	McKesson Corporation	The special sp
14.	Master Consulting Agreement, dated October 19, 2021, by and between Acorda Therapeutics Inc. and Dennis Brodsky	Dennis Brodsky	atanggatt.
15.	Master Consulting Agreement, dated December 31, 2023, by and between Acorda	Alex Bonacum	Fig. 1. Ship of the state of th

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Alex Bonacum		
16.	Master Consulting Agreement, dated. April 24, 2017, by and between Acorda Therapeutics Inc. and Pharmacovigilance Physician Services LLC	Pharmacovigilance Physician Services LLC	-
17.	Master Consulting Agreement, dated as of November 13, 2020, by and between Acorda Therapeutics, Inc. and Opus Regulatory, Inc.	Opus Regulatory, Inc.	-
18.	Master Consulting Agreement, dated January 10, 2023, by and between Acorda Therapeutics, Inc. and Alex Bonacum	Alex Bonacum	-
19.	Master Consulting Agreement, dated as of February 15, 2024, by and between Acorda Therapeutics, Inc. and Gilani, LLC	Gilani LLC	\$6,000.00
20.	Schedule #1 under the Master Consulting Agreement, dated as of March 1, 2024, by and between Acorda Therapeutics, Inc. and Scientific Research Partners, LLC	Scientific Research Partners, LLC	-
21.	Master Consulting Agreement, dated as of January 8, 2024, by and between Acorda Therapeutics, Inc. and Manfred Fischer Consulting	Scientific Research Partners, LLC	-
22.	Master Consulting Agreement, dated as of March 1, 2024, by and between Acorda Therapeutics, Inc. and Scientific Research Partners, LLC	Scientific Research Partners, LLC	-
23.	Master Consulting Agreement, dated as of January 1, 2024, by and between Acorda Therapeutics, Inc. and SA Global Solutions, LLC.	SA Global Solutions, LLC	-
24.	Bill of Materials Form, dated as of January 30, 2023, by and	Sharp Corporation	\$8,825.00

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Sharp Corporation and		
	Acorda Therapeutics, Inc.		
25.	Bill of Materials Form, dated	Sharp Corporation	-
	as of March 3, 2022, by and	• •	
	between Sharp Corporation and		
	Acorda Therapeutics, Inc.		
26.	Bill of Materials Form, dated	Sharp Corporation	-
	as of August 14, 2023, by and		
	between Sharp Corporation and		
	Acorda Therapeutics, Inc.		
27.	Documents MBR-0839, MBR-	Catalent Pharma	-
	0840, MBR-0982, MBR-1316,	Solutions	
	MBR-1317 dated as of January		
	4, 2024, by and between		
	Catalent Pharma Solutions and		
	Acorda Therapeutics, Inc.		
28.	Documents MBR-0839, MBR-	Catalent Pharma	-
	0840, MBR-0982, MBR-1303,	Solutions	
	MBR-1304 dated as of January		
	4, 2024, by and between		
	Catalent Pharma Solutions and		
20	Acorda Therapeutics, Inc.	Cham Camanatian	
29.	Bill of Materials Form, dated as of August 31, 2023, by and	Sharp Corporation	-
	between Sharp Corporation and		
	Acorda Therapeutics, Inc.		
30.	Packaging Work Order – Bill	Patheon Inc.	_
30.	of Materials, dated as of April	i anicon nic.	
	13, 2023, by and between		
	Patheon Inc. and Acorda		
	Therapeutics, Inc.		
31.	Processing Master – Cover	Patheon Inc.	-
	Page and Related Documents,		
	dated as of September 29,		
	2023, by and between Patheon		
	Inc. and Acorda Therapeutics,		
	Inc.		
32.	Main Agreement, dated	NDA Group AB	\$18,975.00
	December 16, 2014, by and	_	
	between Acorda Therapeutics,		
	Inc. and NDA Group AB		
33.	Supply Agreement dated as of	Biogen IDEC	-
	June 30, 2009 between Acorda	International	
]	Therapeutics, Inc and Biogen	GMBH	
	IDEC International GMBH		

No.	Contract	Counter Party(s)	Cure Amount (\$)
34.	Collaboration and License Agreement dated as of June 30, 2009, by and between Acorda Therapeutics, Inc. and Biogen IDEC International GmbH	Biogen IDEC International GMBH	-
35.	Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 21, 2010, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
36.	Addendum #2 to the Collaboration and License Agreement, dated as of March 29. 2012, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
37.	Addendum #3 to Collaboration and License Agreement and to Supply Agreement, dated as of February 14, 2013, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
38.	Addendum #4 to the Collaboration and License Agreement, dated as of October 28, 2012, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
39.	Amended and Restated Addendum #2 to the Supply Agreement, dated as of June 6, 2016, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
40.	Amendment #1 to Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 16, 2011, by and between	Biogen IDEC International GMBH	_

No.	Contract	Counter Party(s)	Cure Amount (\$)
_	Acorda Therapeutics, Inc. and Biogen Idec International GmbH		
41.	Amendment #1 to Manufacturing Services Agreement, dated as of August 29, 2011, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
42.	Quality Agreement, dated as of July 20, 2021, by and between Biogen International GmbH and Alkermes Pharma Ireland Limited	Biogen International GmbH	-
43.	Addendum #2 to the Supply Agreement, dated as of August 28, 2010, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
44.	Fampridine Safety Data Exchange Agreement, dated as of May 24, 2023, by and between Acorda Therapeutics, Inc. and Biogen International GmbH	Biogen International GMBH	-
45.	Manufacturing Services Agreement, dated as of December 31, 2022, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	\$1,872,711.06
46.	Asset Purchase and License Agreement, dated as of December 27, 2010, by and between Corregidor Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	\$284,509.55
47.	First Amendment to Manufacturing Services Agreement, dated as of March 6, 2023, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
48.	Quality Agreement, dated as of May 6, 2021, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	-
49.	Amendment to Asset Purchase and License Agreement, dated as of December 9, 2011, by and between Civitas Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	-
50.	Second Amendment to Asset Purchase and License Agreement, dated as of December 19, 2014, by and between Civitas Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	-
51.	Feasibility Study Agreement, dated December 26, 2014, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
52.	Amendment #1 to the Feasibility Study Agreement, dated March 12, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
53.	Amendment #1 to Statement of Work #1, dated March 12, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
54.	Amendment #2 to Statement of Work #1, dated September 16, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
55.	Amendment #3 to Statement of Work #1, dated October 5, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
56.	Master Development and Clinical Supply Agreement, dated September 15, 2015, by and between Acorda	Metrics, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Metrics,		(5)
	Inc.		
57.	Patent License Agreement,	Mayne Pharma,	-
	dated November 1, 2016, by	Inc.	
	and between Acorda		
	Therapeutics, Inc. and Mayne		
	Pharma, Inc. (d/b/a Metrics		
	Contract Services)		
58.	Quote for Analytical	Metrics, Inc.	-
	Development, CTM		
	Manufacture, Release Testing		
	and Stability for Dalfampridine		
	(4-aminopyridine) MR Tablets,		
	22mg, dated as of September		
	24, 2015, from Metrics		
	Contract Services to Acorda		
-	Therapeutics, Inc.	7	
59.	Statement of Work #1, dated	Metrics, Inc.	-
	January 5, 2015, by and		
	between Acorda Therapeutics,		
-	Inc. and Metrics, Inc.	CVG C	
60.	Medicare Part D Rebate	CVS Caremark Part	-
1	Agreement, dated as of January 1, 2021, by and between	D Services, L.L.C.	
ļ	Acorda Therapeutics, Inc. and		
	CVS Caremark Part D		
	Services, L.L.C.		
61.	Rebate Agreement, dated as of	CaremarkPCS	-
	July 1, 2015, by and between	Health, L.L.C.	
	Acorda Therapeutics, Inc. and		
	CaremarkPCS Health, L.L.C.		
62.	Medicare Part D Rebate	Elixir Rx Solutions	-
	Agreement, dated as of April 1,	of Nevada, LLC	
	2021, by and between Acorda		
ł	Therapeutics, Inc. and Elixir		
	Rx Solutions of Nevada, LLC		
63.	Rebate Program Agreement,	Ascent Health	\$133,642.11
1	dated as of July 1, 2019, by and	Services LLC	
	between Acorda Therapeutics,		
	Inc. and Ascent Health		
	Services LLC		
64.	Preferred Savings Grid Rebate	Express Scripts,	\$58,258.70
	Program Agreement, dated as	Inc.	
<u></u>	of July 1, 2019, by and		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics,		
	Inc. and Express Scripts, Inc.		
65.	Medicare Part D Rebate	Express Scripts	•
	Agreement, dated as of January	Senior Care	
	1, 2019, by and between	Holdings, Inc.	
	Acorda Therapeutics, Inc. and		
	Express Scripts Senior Care		
	Holdings, Inc.		
66.	Kaiser Permanente Product	Kaiser Foundations	\$17,048.51
	Rebate and Discount	Hospitals	
	Agreement, dated as of	Kaiser Foundation	
	September 1, 2020, by and	Health Plan, Inc.	
	between Acorda Therapeutics,		
İ	Inc., Kaiser Foundations		
	Hospitals and Kaiser		
	Foundation Health Plan, Inc.		
67.	Rebate and Administrative Fee	Navitus Health	-
	Agreement, dated as of January	Solutions, LLC	
1	1, 2021, by and between		
	Acorda Therapeutics, Inc. and		
	Navitus Health Solutions, LLC		
68.	Medicare Part D Rebate	OptumRx, Inc.	-
l	Agreement, dated as of January		
	1, 2016, by and between		
	Acorda Therapeutics, Inc. and		
	OptumRx, Inc.		
69.	Rebate Agreement, dated as of	OptumRx, Inc.	-
	January 1, 2013, by and		
	between Acorda Therapeutics,		
70.	Inc. and OptumRx, Inc. Commercial Rebate	Zinc Health	\$2.42.440.02
70.			\$342,440.03
	Agreement, dated as of January 1, 2021, by and between	Services, LLC	
	Acorda Therapeutics, Inc. and		
	Zinc Health Services, LLC		
71.	Second Amendment to Supply	AmerisourceBergen	
/1.	Agreement, dated as of	Drug Corporation	_
	February 4, 2010, by and	Drug Corporation	
	between AmerisourceBergen		
	Drug Corporation and Acorda		
	Therapeutics, Inc.		
72.	Letter re Inbrija Return Goods	AmerisourceBergen	_
12.	Policy Notice Amendment,	Drug Corporation	
	dated as of November 22,	Diag Corporation	
	2019, by and among Acorda		
	1 2017, by and annoing Acorda	l	<u> </u>

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc., ASD Specialty Healthcare, Inc. and AmerisourceBergen Specialty Group, Inc.	ino Arra Major II Jana San Hand II wanna	agend Fabrick in a start Z
73.	Seventh Amendment to Distribution Services Agreement, dated as of February 1, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, LLC	ASD Specialty Healthcare, LLC	
74.	Supply Agreement, dated as of September 20, 2004, by and between Acorda Therapeutics, Inc. and AmerisourceBergen Drug Corporation	AmerisourceBergen Drug Corporation	ending
75.	Amendment to Supply Agreement, dated as of May 1, 2008, by and between AmerisourceBergen Drug Corporation and Acorda Therapeutics, Inc.	AmerisourceBergen Drug Corporation	
76.	Ninth Amendment to Distribution Services Agreement, dated as of September 6, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, LLC.	ASD Specialty Healthcare, LLC	- And Architecture of a 2 control of
77.	Distribution Services Agreement, dated as of February 1, 2011, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, LLC.	\$19,888.80
78.	Quality Agreement, dated as of April 4, 2019, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	The global state of the gl
79.	U.S. Principal Party in Interest (USPPI) Affidavit and Power of Attorney, dated as of August 22, 2017, by and among Acorda Therapeutics, Inc.,	Cardinal Health 105 Inc. Cardinal Health 110, Inc.	Lag gradiense, i 1 march program gradien en up, 1 march Sentenser march en up, 1 march Sentenser march

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Cardinal Health 105 Inc. and Cardinal Health 110, Inc.		
80.	Letter re amendment to Operating Guidelines, dated as of March 3, 2020, by and between Cardinal Health Specialty Solutions and Acorda Therapeutics, Inc.	Cardinal Health Specialty Solutions	-
81.	Third Amendment to Distribution Agreement, dated as of September 28, 2012 by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	_
82.	Distribution Agreement, dated as of August 19, 2004, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc. f.k.a. Cardinal Health PTS, LLC	Cardinal Health 105, Inc. f.k.a. Cardinal Health PTS, LLC	_
83.	U.S. Principal Party in Interest (USPPI) Affidavit, dated as of January 8, 2019, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
84.	U.S. Principal Party in Interest (USPPI) Affidavit, dated as of December 2, 2020, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
85.	First Amendment to Distribution Agreement, dated as of July 26, 2005, by and between Cardinal Health PTS, LLC and Acorda Therapeutics, Inc.	Cardinal Health PTS, LLC	-
86.	Second Amendment to Distribution Agreement, dated as of January 22, 2010, by and between Cardinal Health 105, Inc. and Acorda Therapeutics, Inc.	Cardinal Health 105, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
87.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and among Acorda Therapeutics, Inc., Express Scripts, Inc. and Accredo Health Group, Inc. Product Purchase and	Express Scripts, Inc. Accredo Health Group, Inc. Accredo Health	Exp 20 Finduction in the control of
	Dispensing Agreement, dated as of April 15, 2016, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Group, Inc.	the application of the state of
89.	4 th Amendment to Pharmacy Services Agreement, dated as of April 22, 2021, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	THE COMMENT OF THE COMME
90.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of July 1, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	
91.	First Amendment to Specialty Pharmacy Services Agreement, dated as of April 20, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	The special control of
92.	Third Amendment to Specialty Pharmacy Data Services Agreement, dated as of June 25, 2015, by and between Acorda Therapeutics, Inc. and Accredo Health Group Inc.	Accredo Health Group, Inc.	Addition of the state of the st
93.	Third Amendment to Specialty Pharmacy Purchase and Dispensing Agreement, dated as of June 25, 2015, by and between Acorda Therapeutics, Inc. and Accredo Health Group Inc.	Accredo Health Group, Inc.	Language of the start of the st

No.	Contract	Counter Party(s)	Cure Amount (\$)
94.	Pharmacy Services Agreement	Accredo Health	\$57,515.00
	dated as of April 15, 2016, by	Group, Inc.	
	and between Acorda		
	Therapeutics, Inc. and Accredo		
	Health Group, Inc.		
95.	Specialty Pharmacy Data	Accredo Health	-
	Services Agreement dated as of	Group, Inc.	
	February 26, 2010, by and		
	between Acorda Therapeutics,		
	Inc. and Accredo Health		
	Group, Inc.		
96.	Specialty Pharmacy Purchase	Accredo Health	-
	and Dispensing Agreement,	Group, Inc.	
	dated as of February 26, 2010,		
	by and between Acorda		
	Therapeutics, Inc. and Accredo		
	Health Group, Inc.		
97.	Third Amendment to Specialty	Accredo Health	-
	Pharmacy Services Agreement,	Group, Inc.	
	dated as of April 1, 2020, by		
1	and between Acorda		
	Therapeutics, Inc. and Accredo		
	Health Group, Inc.	4 7 77 1.1	
98.	Second Amendment to	Accredo Health	-
	Specialty Pharmacy Services	Group, Inc.	
	Agreement, dated as of July 1,		
	2018, by and between Acorda		
	Therapeutics, Inc. and Accredo		
99.	Health Group, Inc. Draft Sixth Amendment to	Caramark I I C	\$22.714.72
33. 	Specialty Pharmacy Purchase	Caremark, L.L.C.	\$33,714.73
	and Dispensing Agreement, by		
	and between Acorda		
	Therapeutics, Inc. and		
	Caremark, L.L.C.		
100.	Third Amendment to Pharmacy	Caremark, L.L.C.	-
	Services Agreement, dated as		
	of December 31, 2020, by and		
	between Acorda Therapeutics,		
	Inc. and Caremark, LLC.		
101.	Letter re Inbrija Return Goods	Caremark, L.L.C.	-
	Policy Notice Amendment,		
	dated as of November 22,		
1	2019, by and between Acorda		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Caremark, LLC.	and rown to the	de Kradi over processi.
102.	Pharmacy Services Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and	Caremark, L.L.C.	- INDER DE PARTIE
	Caremark, L.L.C.		
103.	Product Purchase and Dispensing Agreement, dated as of October 1, 2017, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	Here I will be a second of the
104.	Product Purchase and Dispensing Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	Fig. 1. A graph of the line of the last of
105.	Fourth Amendment to Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. And Caremark, L.L.C.	Caremark, L.L.C.	
106.	First Amendment to Pharmacy Services Agreement, dated as of March 26, 2018, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	- It's unitaria of a result of the control of the c
107.	Second Amendment to Pharmacy Services Agreement, dated as of May 1, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	- SCAL PERCONTRACT INDUSTRICATION OF THE PROPERTY OF THE PROP
108.	Pharmacy Services Agreement, dated as of October 1, 2017, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	Entropy (1) and the state of th
109.	First Amendment to Pharmacy Services Agreement, dated as of March 26, 2018, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	

No.	Contract	Counter Party(s)	Cure Amount (\$)
110.	Third Amendment to Pharmacy Services Agreement, dated as of December 31, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
111.	Fourth Amendment to Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
112.	Fifth Amendment to Pharmacy Services Agreement, dated as of March 1, 2022, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
113.	Sixth Amendment to Pharmacy Services Agreement, dated as of May 9, 2022, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	•
114.	Second Amendment to Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
115.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
116.	Second Amendment to Pharmacy Services Agreement, dated as of May 1, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
117.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-

- Cure Amount (\$)
-
_
<u>-</u>
_
_
-
-
•
-
-
-

No.	Contract	Counter Party(s)	Cure Amount (\$)
124.	Project Addendum #2 to the	Covance Market	-
	Master Market Access Services	Access Services	
	Agreement, dated as of May 1,	Inc.	
	2018, by and between Acorda		
	Therapeutics, Inc. and Covance		
	Market Access Services Inc.		
125.	Master Market Access Services	Covance Market	-
	Agreement, dated as of August	Access Services	
	6, 2015, by and between	Inc.	
	Acorda Therapeutics, Inc. and		
	Covance Market Access		
	Services Inc.		
126.	Project Addendum #1 to the	Covance Market	-
	Master Market Access Services	Access Services	
1	Agreement, dated as of	Inc.	
	September 2, 2015, by and		
i	between Acorda Therapeutics,		
	Inc. and Covance Market		
	Access Services Inc.		
127.	Project Addendum #3 to the	Covance Market	-
	Master Market Access Services	Access Services	
	Agreement, dated as of August	Inc.	
	8, 2018, by and between		
	Acorda Therapeutics, Inc. and		
	Covance Market Access		
120	Services Inc.	Ca-din DV In	
128.	Third Amendment to Pharmacy	SterlingRX, Inc.	-
	Services Agreement, dated as		
	of February 15, 2023, by and between Acorda Therapeutics,		
	• •		
129.	Inc. and SterlingRX, Inc. Third Amendment to the	RIS Rx	
129.	Master Patient Support Hub	I NIS NX	-
	Services Agreement, dated as		
	of March 8, 2023, by and		
	between Acorda Therapeutics,		
	Inc. and RIS Rx.		
130.	Second Amendment to Master	SterlingRX, Inc.	_
••••	Direct Product Purchase and		
	Dispensing Agreement, dated		
	as of February 15, 2023, by		
	and between Acorda		
	Therapeutics, Inc. and		
	SterlingRx, Inc.		

No.	Contract	Counter Party(s)	Cure Amount (\$)
131.	Inventory Amendment to	Humana Pharmacy,	-
	Pharmacy Services Agreement,	Inc.	
	dated as of April 1, 2021, by		
	and between Acorda		
	Therapeutics, Inc. and Humana		
	Pharmacy, Inc.		
132.	Letter re Inbrija Return Goods	Humana Pharmacy,	-
	Policy Notice Amendment,	Inc.	
	dated as of November 22,		
	2019, by and between Acorda		
	Therapeutics, Inc. and Humana		
	Pharmacy, Inc.		
133.	Pharmacy Services Agreement,	Humana Pharmacy,	-
	dated as of April 1, 2016, by	Inc.	
	and between Acorda		
	Therapeutics, Inc. and Humana		
134.	Pharmacy, Inc. Product Purchase and	II Dl	
134.		Humana Pharmacy,	-
	Dispensing Agreement, dated	Inc.	
	as of April 1, 2016, by and between Acorda Therapeutics,		
	Inc. and Humana Pharmacy,		
	Inc.		
135.	Inbrija Product Attachment to	Humana Pharmacy,	_
133.	Product Purchase and	Inc.	
	Dispensing Agreement, dated		
	as of February 22, 2019, by		
	and between Acorda		
	Therapeutics, Inc. and Humana		
	Pharmacy, Inc.		
136.	First Amendment to Pharmacy	Humana Pharmacy,	-
	Services Agreement, dated as	Inc.	
	of December 1, 2017, by and		
	between Acord Therapeutics,		
	Inc. and Humana Pharmacy,		
	Inc.		
137.	Second Amendment to	Humana Pharmacy,	-
	Pharmacy Services Agreement,	Inc.	
	dated as of April 1, 2016, by		
	and between Acorda	1	
	Therapeutics, Inc. and Humana		
120	Pharmacy, Inc.	TT. Di	
138.	Inbrija Product Attachment to	Humana Pharmacy,	-
	Pharmacy Services Agreement,	Inc.	
	dated as of March 21, 2019, by		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	and between Acorda		
	Therapeutics, Inc. and Humana		
	Pharmacy, Inc.		
139.	Fourth Amendment to	BriovaRx of Maine,	-
	Specialty Pharmacy Services	Inc.	
	Agreement, dated as of May 1,		
l	2021, by and between Acorda		
	Therapeutics, Inc. and		
140	BriovaRx of Maine, Inc.	D: D CM:	
140.	Product Purchase and	BriovaRx of Maine,	-
	Dispensing Agreement, dated	Inc.	
	as of April 1, 2016, by and between Acorda Therapeutics,		
	Inc. and BriovaRx of Maine		
	Inc.		
141.	Pharmacy Services Agreement,	BriovaRx of Maine,	\$68,380.00
141.	dated as of April 1, 2016, by	Inc.	406,360.00
	and between Acorda, by and	inc.	
	Therapeutics, Inc. and		
	BriovaRx of Maine Inc.		
142.	Specialty Pharmacy Data	BriovaRx of Maine,	-
	Services Agreement, dated as	Inc.	
	of January 8, 2015, by and		
	between Acorda Therapeutics,		
ŀ	Inc. and BriovaRx of Maine		
	Inc.		
143.	Letter re Inbrija Return Goods	BriovaRx of Maine,	-
	Policy Notice Amendment,	Inc.	
	dated as of November 22,		
	2019, by and between Acorda		
	Therapeutics, Inc. and		
	BriovaRx of Maine, Inc. and		
144	Optum Rx, Inc.	D.:DC) (-:	
144.	First Amendment to Inbrija	BriovaRx of Maine,	-
	Product Attachment to	Inc.	
	Pharmacy Services Agreement, dated as of November 1, 2019,		
	by and between Acorda		
	Therapeutics, Inc. and		
	BriovaRx of Maine, Inc.		
145.	Third Amendment to Specialty	BriovaRx of Maine,	_
1.5.	Pharmacy Services Agreement,	Inc.	
	dated as of April 1, 2020, by		
	and between Acorda		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and BriovaRx of Maine, Inc.		Mars Tolly 1907 F
146.	First Amendment to Specialty Pharmacy Services Agreement, dated as of March 1, 2018, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	
147.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of March 1, 2018, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	
148.	Inbrija Product Attachment to Product Purchase and Dispensing Agreement, dated as of January 3, 2019, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	
149.	Product Purchase and Dispensing Agreement, dated as of August 31, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	
150.	Pharmacy Services Agreement, dated as of August 31, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	\$80,951.54
151.	Pharmacy Services Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	
152.	Pharmacy Services Agreement, dated as of September 1, 2017, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	\$41,540.00
153.	Product Purchase and Dispensing Agreement, dated as of September 1, 2017, by and between Acorda	Walgreen Co.	Jennier der Steiner der Steine

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and		
	Walgreen Co.		
154.	Letter re Inbrija Return Goods	Walgreens Co.	-
	Policy Notice Amendment,	Walgreens	
	dated as of November 22,	Specialty	
	2019, by and among Acorda	Pharmacy, L.L.C.	
	Therapeutics, Inc. and		
	Walgreens Co. and Walgreens		
	Specialty Pharmacy, L.L.C.		
155.	Amendment No. 1 to Ampyra	Walgreen Co.	-
	Pharmacy Services Agreement,		
	dated as of April 28, 2020, by		
	and between Acorda		
	Therapeutics, Inc. and		
156	Walgreen Co.	4.670.0	
156.	First Amendment to	ASD Specialty	-
	Distribution Services	Healthcare, Inc.	
	Agreement, dated as of July 13,		
	2011, by and between Acorda Therapeutics, Inc. and ASD		
	Specialty Healthcare, Inc.		
157.	Second Amendment to	ASD Specialty	
157.	Distribution Services	Healthcare, Inc.	-
	Agreement, dated as of	Ticalticale, iiic.	
	November 14, 2012, by and		
	between Acorda Therapeutics,		
	Inc. and ASD Specialty		
	Healthcare, Inc.		
158.	Third Amendment to	ASD Specialty	-
	Distribution Services	Healthcare, Inc.	
	Agreement, dated as of July 1,		
	2014, by and between Acorda		
	Therapeutics, Inc. and ASD		
	Specialty Healthcare, Inc.		
159.	Fourth Amendment to	ASD Specialty	-
	Distribution Services	Healthcare, Inc.	
	Agreement, dated as of		
	November 4, 2014, by and		
	between Acorda Therapeutics,		
	Inc. and ASD Specialty		
1.60	Healthcare, Inc.	1.00.0	
160.	Fifth Amendment to	ASD Specialty	-
	Distribution Services	Healthcare, Inc.	
	Agreement, dated as of		
	December 22, 2014, by and		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	,	
161.	Sixth Amendment to Distribution Services Agreement, dated as of October 21, 2015, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
162.	Seventh Amendment to Distribution Services Agreement, dated as of February 1, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
163.	Eighth Amendment to Distribution Services Agreement, dated as of June 25, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
164.	Ninth Amendment to Distribution Services Agreement, dated as of September 6, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
165.	Amendment No. 1 to Master Specialty Pharmacy Services Agreement, dated as of August 1, 2020, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC.	Covance Specialty Pharmacy LLC.	-
166.	Change Order #1 to Project Addendum #1 to the Master Specialty Pharmacy Services Agreement, dated as of January 1, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
167.	Change Order #2 to Project Addendum #1 to the Master Specialty Pharmacy Services Agreement, dated as of January 20, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-
168.	Project Addendum #1 to the Master Market Access Services Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC.	Covance Specialty Pharmacy LLC	-
169.	Project Addendum #2 to the Master Market Access Services Agreement, dated as of May 1, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
170.	Change Order #2 to Project Addendum #2 to the Master Market Access Services Agreement, dated as of October 30, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
171.	Change Order #2 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
172.	Change Order #2 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
173.	Change Order #3 to Project	Covance Market	-
1	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of May		
	22, 2019, by and between		
	Acorda Therapeutics, Inc. and		
	Covance Market Access		
	Services Inc.		
174.	Change Order #4 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of June		
	15, 2019, by and between		
	Acorda Therapeutics, Inc. and		
	Covance Market Access		
	Services Inc.		
175.	Change Order #7 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of		
	February 10, 2020, by and		
	between Acorda Therapeutics,		
	Inc. and Covance Market		
	Access Services Inc.		
176.	Change Order #8 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of May		
	11, 2020, by and between		
	Acorda Therapeutics, Inc. and		
1	Covance Market Access	•	
155	Services Inc.	0 3/	
177.	Change Order #9 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of May		
1	11, 2020, by and between		
1	Acorda Therapeutics, Inc. and		
	Covance Market Access		
178.	Services Inc.	Covance Market	
1/8.	Change Order #1 to Project Addendum #2 and #3 to the	Access Services	-
	Master Market Access Services	Inc.	
	Agreement, dated as of	IIIC.	
	September 18, 2018, by and		
L	1 September 10, 2010, by allu		l

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics,		
	Inc. and Covance Market		
	Access Services Inc.		
179.	Change Order #12 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of April 1,		
	2021, by and between Acorda		
	Therapeutics, Inc. and Covance		
	Market Access Services Inc.		
180.	Change Order #10 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of May		
	27, 2020, by and between		
	Acorda Therapeutics, Inc. and		
	Covance Market Access		
	Services Inc.		
181.	Change Order #11 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of July 17,		
	2020, by and between Acorda		
	Therapeutics, Inc. and Covance		
100	Market Access Services Inc.		
182.	Change Order #6 to Project	Covance Market	-
	Addendum #3 to the Master	Access Services	
	Market Access Services	Inc.	
	Agreement, dated as of		
	February 24, 2020, by and		
	between Acorda Therapeutics,		
	Inc. and Covance Market		
183.	Access Services Inc.	Covance Market	
103.	Change Order #1 to Project Addendum #1 to the Master	Access Services	-
	Market Access Services	Inc.	
	Agreement, dated as of May	IIIC.	
	20, 2016, by and between		
	Acorda Therapeutics, Inc. and		
	Covance Market Access		
	Services Inc.		
184.	Confidential Disclosure	Covance Market	_
107.	Agreement, dated as of May	Access Services	_
	26, 2017, by and between	Inc.	
	Covance Market Access	1110.	
	1 CO TUILOU ITIUI NOL / 100033	<u>L.</u> .	

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Services Inc. and Acorda		
	Therapeutics, Inc.		
185.	Project Addendum #4 to the	Covance Market	\$310,036.54
	Master Market Access Services	Access Services	
	Agreement, dated as of June	Inc.	
	22, 2018, by and between		
	Covance Market Access		
	Services Inc. and Acorda		
	Therapeutics, Inc.		
186.	Master Market Access Services	Covance Market	-
	Agreement, dated as of August	Access Services	
	6, 2015, by and between	Inc.	
	Covance Market Access		
	Services Inc. and Acorda		
	Therapeutics, Inc.		
187.	Project Addendum #5 to	Labcorp Peri-	-
	Master Market Access Services	Approval and	
	Agreement, dated as of January	Commercialization	
	1, 2022, by and between	Inc.	
	Labcorp Peri-Approval and		
	Commercialization Inc. and		
	Acorda Therapeutics, Inc.		
188.	Project Addendum #1 to	Covance Market	-
	Master Market Access Services	Access Services	
	Agreement, dated as of	Inc.	
	September 2, 2015, by and		
	between Covance Market		
	Access Services Inc. and		
	Acorda Therapeutics, Inc.		
189.	Project Addendum #3, dated as	Covance Market	-
	of August 8, 2018, by and	Access Services	
	between Covance Market	Inc.	
	Access Services Inc. and		
100	Acorda Therapeutics, Inc.		
190.	Change Order #2 to Project	Fortrea Specialty	\$22,914.22
	Addendum #1, dated as of	Pharmacy LLC	
	January 1, 2024, by and		
[between Fortrea Specialty		
	Pharmacy LLC and Acorda		
101	Therapeutics, Inc.		
191.	Second Amendment to Master	Fortrea Specialty	-
	Specialty Pharmacy Services	Pharmacy LLC	
	Agreement, dated as of May 1,		
	2023, by and between Fortrea		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Specialty Pharmacy LLC and		
	Acorda Therapeutics, Inc.		
192.	Amendment #1 to Master	Covance Specialty	-
	Specialty Pharmacy Services	Pharmacy LLC	
	Agreement, dated as of August		
	1, 2020, by and between		
	Covance Specialty Pharmacy		
	LLC and Acorda Therapeutics,		
	Inc.		
193.	Change Order #1 to Project	Labcorp Specialty	-
	Addendum #1, dated as of	Pharmacy LLC	
	January 1, 2022, by and		
	between Labcorp Specialty		
ŀ	Pharmacy LLC and Acorda		
	Therapeutics, Inc.		
194.	Master Specialty Pharmacy	Fortrea Specialty	-
İ	Services Agreement, dated as	Pharmacy LLC	
	of July 19, 2018, by and		
	between Acorda Therapeutics,		
	Inc. and Fortrea Specialty		
ı	Pharmacy LLC (f/k/a Covance		
	Specialty Pharmacy LLC)		
195.	Project Addendum #1, dated as	Covance Specialty	 -
	of July 19, 2018, by and	Pharmacy LLC	
	between Covance Specialty		
	Pharmacy LLC and Acorda		
106	Therapeutics, Inc.	T 1 0 11	
196.	Change Order #2 to Project	Labcorp Specialty	-
	Addendum #1, dated as of	Pharmacy LLC	
	January 20, 2022, by and		
	between Labcorp Specialty		
	Pharmacy LLC and Acorda		
197.	Therapeutics, Inc.	Gentry Usalth	\$10,670,00
197.	Specialty Pharmacy Purchase and Dispensing Agreement,	Gentry Health Services Inc.	\$19,670.00
	dated as of September 28,	Services inc.	
	2023, by and between Acorda		
	Therapeutics, Inc. and Gentry		
	Health Services Inc.		
198.	Specialty Pharmacy Services	Gentry Health	-
170.	Agreement, dated as of	Services Inc.	
	September 28, 2023, by and	GCI VICES IIIC.	
	between Acorda Therapeutics,		
	Inc. and Gentry Health		
	Services Inc.		
	301 / 1003 1110.	L	

No.	Contract	Counter Party(s)	Cure Amount (\$)
199.	Trading Partner Account Set- up Form, dated as of September 19, 2019, by and between University of Wisconsin Hospitals and Clinics and Acorda Therapeutics, Inc.	University of Wisconsin Hospitals and Clinics	Al Paramer A off or the off of th
200.	Inflation Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Ascent Health Services LLC	Ascent Health Services LLC	
201.	Inflation Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Express Scripts, Inc.	Express Scripts, Inc.	
202.	Medicare Part D Rebate Inflation Agreement, dated as of July 1, 2020, by and between Acorda Therapeutics, Inc. and Express Scripts Senior Care Holdings, Inc.	Express Scripts Senior Care Holdings, Inc.	
203.	Amendment to Distribution Agreement for Spain, dated as of November 8, 2021, by and between Esteve Pharmaceuticals, S.A. and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, S.A.	
204.	Distribution Agreement, dated as of July 20, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals, S.A.	Esteve Pharmaceuticals, S.A.	
205.	Supply Agreement, dated as of May 3, 2023, by and between Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co., Ltd.	Hangzhou Chance Pharmaceuticals Co., Ltd.	
206.	Exclusive Distribution Agreement, dated as of May 3, 2023, by and between Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co., Ltd.	Hangzhou Chance Pharmaceuticals Co., Ltd.	

Contract	Counter Party(s)	Cure Amount (\$)
Distribution Agreement, dated	Esteve	-
as of November 8, 2021, by	Pharmaceuticals	
and between Acorda	GmbH	
Therapeutics, Inc. and Esteve		
	-	-
	GmbH	
· ·		
	Pharma Congulting	_
		-
	Gloup, S.A.	
•		
	Pharma Consulting	-
May 11, 2022, by and between	Group, S.A.	
Acorda Therapeutics, Inc. and	-	
Pharma Consulting Group,		
		-
•	1	
<u>-</u>	S.A.	
	Fatarra	
		-
	Ginori	
Pharmaceuticals GmbH and		
Acorda Therapeutics, Inc.	,	
Amendment to Supply	Esteve	-
Agreement for Germany, dated	Pharmaceuticals,	
as of May 23, 2023, by and	GmbH	
between Esteve		
		-
	GMDH	
	Adoh B V	_
	Addit D. V.	
-		
-		
	Distribution Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH Supply Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH Distribution Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A. Supply Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A. Supply Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A. Supply Agreement, dated as of July 20, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals, S.A. Amendment to Distribution Agreement for Germany, dated as of May 23, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc. Amendment to Supply Agreement for Germany, dated as of May 23, 2023, by and	Distribution Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH Supply Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH Distribution Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A. Supply Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A. Supply Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A. Supply Agreement, dated as of July 20, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals, S.A. Amendment to Distribution Agreement for Germany, dated as of May 23, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc. Amendment to Supply Agreement, dated as of May 23, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc. First Amendment to the Supply Agreement, dated as of May 10, 2022, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc. Quality Agreement, dated as of September 19, 2022, by and between Acorda Therapeutics, Inc. Quality Agreement, dated as of September 19, 2022, by and between Acorda Therapeutics, Inc. Adoh B.V.

No.	Contract	Counter Party(s)	Cure Amount (\$)
216.	General Service Agreement	Adoh B.V.	\$14,524.17
	dated as of October 16, 2018		
	between Acorda Therapeutics,		
	Inc., Acorda Therapeutics		
	Ireland Limited and Adoh B.V.		
217.	Importer Agreement, dated as	MedEnvoy Global	-
	of August 4, 2021, by and	B.V.	
	between Acorda Therapeutics,		
	Inc. and MedEnvoy Global		
	B.V.		
218.	Safety Data Exchange	Esteve	-
l	Agreement, dated as of	Pharmaceuticals	
	November 30, 2023, by and	GMBH	
	among Acorda Therapeutics,	Esteve	
	Inc., Esteve Pharmaceuticals	Pharmaceuticals	
	GMBH and Esteve	S.A.	
	Pharmaceuticals S.A.	T .	
219.	Third Amendment to the	Esteve	-
	Distribution Agreement for	Pharmaceuticals	
	Germany, dated as of	GMBH	
	December 14, 2023, by and		
	between Esteve		
	Pharmaceuticals GmbH and		
220.	Acorda Therapeutics, Inc. Second Amendment to the	Esteve	
220.	Distribution Agreement for	Pharmaceuticals	-
	Germany, dated as of	GmbH	
	December 14, 2023, by and	Gillori	
	between Esteve		
	Pharmaceuticals GmbH and		
l	Acorda Therapeutics, Inc.		
221.	First Amendment to the	CVS Caremark Part	\$141,601.71
1.	Medicare Part D Program	D Services, LLC	, , , , , , , , , , , , , , , , , , , ,
	Rebate Agreement, dated as of		·
	January 1, 2022, by and		
	between CVS Caremark Part D		
	Services, LLC and Acorda		
	Therapeutics, Inc.		
222.	Medicare Part D Rebate	OptumRx, Inc.	-
	Agreement, dated as of January	•	
1	1, 2016, by and between		
	Acorda Therapeutics, Inc. and		
	OptumRx, Inc.		
223.	Rebate Agreement, dated as of	OptumRx, Inc.	-
	January 1, 2013, by and		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics,		
	Inc. and OptumRx, Inc.		
224.	Sixth Amendment to the	OptumRx, Inc.	\$109,300.76
	Medicare Part D Rebate	_	
	Agreement, dated as of January		
	1, 2023, by and between		
	OptumRx, Inc. and Acorda		
	Therapeutics, Inc.		
225.	First Amendment to the Master	Riparian LLC	-
	Services Agreement, dated as		
	of March 9, 2023, by and		
	between Riparian LLC and		
	Acorda Therapeutics, Inc.		
226.	Master Services Agreement,	TrialCard	-
	dated as of January 16, 2019,	Incorporated	
	by and between Acorda		
	Therapeutics, Inc. and		
	TrialCard Incorporated	<u> </u>	
227.	Master Services Agreement,	Riparian LLC	-
	dated as of April 15, 2020, by		
	and between Acorda		
	Therapeutics, Inc. and		
222	Riparian, LLC		
228.	Statement of Work #3, dated as	Riparian LLC	-
	of September 28, 2023, by and		
	between Riparian LLC and		
220	Acorda Therapeutics, Inc.	T-:-1C1	
229.	TrialCard Statement of Work:	TrialCard	-
	2023 Engage HCP PTR	Incorporated	
	Program (Inside Sales		
	Program), dated as of January 1, 2023, by and between		
	TrialCard Incorporated and		
	Acorda Therapeutics, Inc.		
230.	First Amendment to the Master	TrialCard	
250.	Services Agreement, dated as	Incorporated	-
	of July 15, 2022, by and	moorporateu	
	between TrialCard		
	Incorporated and Acorda		
	Therapeutics, Inc.		
231.	TrialCard Statement of Work	TrialCard	_
231.	Inbrija Copay Program Change	Incorporated	
	Order Number 6, dated as of		
	January 1, 2023, by and		
	between TrialCard		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Incorporated and Acorda		
	Therapeutics, Inc.		
232.	Third Amendment to the	TrialCard	-
	Master Services Agreement,	Incorporated	
	dated as of November 15,	'	
	2023, by and between		
	TrialCard Incorporated and		
	Acorda Therapeutics, Inc.		
233.	TrialCard Statement of Work	TrialCard	-
i	Change Order Number 1:	Incorporated	
l	Inbrija Co-pay Program, dated		
1	as of September 5, 2019, by		
	and between TrialCard	i	
1	Incorporated and Acorda	!	
	Therapeutics, Inc.		
234.	TrialCard Statement of Work	TrialCard	-
	Change Order Number 2:	Incorporated	
	Inbrija Co-pay Program, dated		
	as of February 1, 2020, by and		
	between TrialCard		
	Incorporated and Acorda		
	Therapeutics, Inc.		
235.	TrialCard Statement of Work:	TrialCard	-
	Co-pay Services: Inbrija Co-	Incorporated	
	pay Program, dated as of		
	January 16, 2019, by and		
	between TrialCard		
	Incorporated and Acorda		
	Therapeutics, Inc.		
236.	Statement of Work: 2024	Mercalis Inc.	-
	Inbrija Copay Program, dated		
	as of January 1, 2024, by and		
	between Mercalis Inc. and		
	Acorda Therapeutics, Inc.		
237.	TrialCard Statement of Work	TrialCard	-
	Change Order Number 3:	Incorporated	
	Inbrija Co-pay Program, dated		
	as of May 8, 2020, by and		
	between TrialCard		
	Incorporated and Acorda		
	Therapeutics, Inc.		
238.	Second Amendment to the	TrialCard	-
	Master Services Agreement,	Incorporated	
	dated as of January 11, 2023,		
	by and between TrialCard	1	

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Incorporated and Acorda		
	Therapeutics, Inc.		
239.	TrialCard Statement of Work	TrialCard	-
	Inbrija Copay Program:	Incorporated	
	Change Order Number 7, dated	-	
	as of March 24, 2022, by and		
	between TrialCard		
	Incorporated and Acorda		
	Therapeutics, Inc.		
240.	Statement of Work: Acorda	Mercalis Inc.	-
	Therapeutics, Inc. 2024 Inside		
	Sales Program, dated as of		
	January 1, 2024, by and		
	between Mercalis Inc. and		
	Acorda Therapeutics, Inc.		
241.	TrialCard Statement of Work:	TrialCard	-
	Ampyra Copay Assistance	Incorporated	
	Program, dated as of August 1,		
	2022, by and between		
	TrialCard Incorporated and		
	Acorda Therapeutics, Inc.		
242.	TrialCard Statement of Work	TrialCard	-
	Change Order Number 4:	Incorporated	
	Inbrija Co-pay Program, dated		
	as of March 1, 2021, by and		
	between TrialCard		
	Incorporated and Acorda		
243.	Therapeutics, Inc. TrialCard Statement of Work	TrialCard	
243.	· · · ·		-
	Change Order Number 5: Inbrija Co-pay Program, dated	Incorporated	
	as of April 2, 2021, by and		
	between TrialCard		
	Incorporated and Acorda		
	Therapeutics, Inc.		
244.	Confidential Disclosure	Regis	-
- ' ' '	Agreement, dated as of May	Technologies, Inc.,	
	28, 2009, by and among Regis	Bayer HealthCare	
	Technologies, Inc., Bayer	Pharmaceuticals	
	HealthCare Pharmaceuticals	Inc.	
	Inc. and Acorda Therapeutics,		
	Inc.		
245.	Amendment #1 to Master	Regis	-
	Services Agreement, dated as	Technologies, Inc.	
	of March 5, 2010, by and		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Lection in	of each fitte for the second of the second o
246.	Amendment #2 to Master Services Agreement, dated as of March 4, 2012, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	Final Control
247.	Amendment #3 to Master Services Agreement, dated as of March 3, 2013, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	E. 10 G TO TO RELEASE TO THE SECOND STATE OF T
248.	Confidential Disclosure Agreement, dated as of February 7, 2008, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	The first of the second of the
249.	Confidential Disclosure Agreement, dated as of June 3, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	Frequency of the second of the
250.	Consent Letter, dated as of May 18, 2009, by and among Regis Technologies, Inc., SmithKline Beecham Corporation, and Acorda Therapeutics, Inc.	Regis Technologies, Inc. SmithKline Beecham Corporation	Figure Louds pour les de la company de la co
251.	Master Service Agreement, dated as of May 5, 2009, by and between Acorda Therapeutics, Inc. and Regis Technologies Inc.	Regis Technologies Inc.	
252.	Mutual Confidentiality and Non-Disclosure Agreement, dated as of October 1, 2009, by and among J-Star Research, Regis Technologies, Inc. and Acorda Therapeutics, Inc.	J-Star Research Regis Technologies, Inc.	ender I in the way of the last of the second
253.	Project Addendum #10, dated as of July 25, 2011, by and	Regis Technologies Inc.	ed at super a succession

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.		
254.	Project Addendum #11, dated as of March 6, 2012, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
255.	Project Addendum #2, dated as of March 9, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
256.	Project Addendum #3, dated as of May 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
257.	Project Addendum #4, dated as of August 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
258.	Project Addendum #5, dated as of August 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
259.	Project Addendum #6, dated as of September 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
260.	Project Addendum #8, dated as of May 7, 2010, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
261.	Project Addendum #9, dated as of April 6, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
262.	Project Addendum #9, dated as of September 27, 2010, by and	Regis Technologies Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	2.20	With the Town
263.	Quality Agreement, dated as of April 1, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	And the second of the second o
264.	Amendment #4 to Master Services Agreement, dated as of October 9, 2018, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	
265.	Certificate of Analysis, dated as of April 1, 1987, prepared by Regis Technologies, Inc.	Regis Technologies Inc.	buts of Maria
266.	Supply Agreement, dated as of April 1, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	
267.	Amendment #5 to Master Services Agreement, dated as of January 29, 2024, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	
268.	Letter Agreement on Confidential Treatment of Third Party Transaction Information, dated as of July 14, 2017, by and among Sharp Corporation, Alkermes Pharma Ireland Limited, and Acorda Therapeutics, Inc.	Sharp Corporation Alkermes Pharma Ireland Limited	
269.	Four-Way Confidentiality Agreement dated as of July 18, 2017 between Acorda Therapeutics, Inc., Covis Pharma B.V., Alkermes Pharma Ireland Limited and Sharp Corporation	Covis Pharma B.V. Alkermes Pharma Ireland Limited Sharp Corporation	Eligin of the second sequents and the second sequents and the second sequents and the second sequents and the second sequents and the second sequents and the second sequents and the second sequents and the second sequents and the second sequents and the second sequents are sequents as the second sequents and the second sequents are sequents as the second sequents are sequents as the second sequents are sequents as the second sequents are sequents as the second sequents are sequents as the second sequents are sequents as the second sequents are sequents as the second sequents are sequents as the second sequents are sequents as the sequents are seq
270.	Agreement on Confidential Treatment of Third Party Transaction Information, dated as of July 13, 2017, by and	Alkermes Pharma Ireland Limited	- (c) A for the form

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Alkermes Pharma		
	Ireland Limited and Acorda		
	Therapeutics, Inc.		
271.	Letter Agreement on	Alkermes Pharma	-
	Subcontract of Certain	Ireland Limited	
	Packaged Product Release and		
	Quality Responsibilities by		
	Alkermes to Acorda for		
	Ampyra, Zanaflex and		
	Tizanidine, dated as of May 5,		
	2016, by and between		
	Alkermes Pharma Ireland		
	Limited and Acorda		
	Therapeutics, Inc.		
272.	Contract Packaging Quality	Alkermes Pharma	-
	Agreement, dated as of May	Ireland Limited	
	12, 2016, by and among		
	Acorda Therapeutics, Inc.,		
	Sharp Corporation and		
	Alkermes Pharma Ireland		
	Limited		
273.	Confidential Disclosure	Sharp Corporation	-
	Agreement, dated as of		
	December 13, 2012, by and		
<u> </u>	between Sharp Corporation and		
	Acorda Therapeutics, Inc.		
274.	Packaging and Supply	Sharp Packaging	-
	Agreement, dated as of	Services, LLC	
	December 31, 2016, by and	,	
	between Acorda Therapeutics,		
	Inc. and Sharp Packaging		
	Services, LLC		
275.	Quality Agreement, dated as of	Sharp Corporation	-
	October 16, 2017, by and	_ •	
	between Acorda Therapeutics,		
	Inc. and Sharp Corporation		<u> </u>
276.	First Amendment to the	Sharp Packaging	-
	Packaging and Supply	Services, LLC	
	Agreement, dated as of		
	December 13, 2022, by and		
	between Sharp Packaging		
	Services, LLC and Acorda		
	Therapeutics, Inc.		
277.	Quality Agreement, dated as of	Qualicaps, Inc.	-
	November 28, 2018, by and		

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Qualicaps, Inc. and		endles de la la collection de la collect
	Acorda Therapeutics, Inc.	51	er. F. Imada div. of Leg. 1
278.	Amendment No. 1 to	Patheon, Inc.	- April 1 1 1
	Commercial Quality	of connecte	n - Restuce - III
	Agreement, dated as of	new Howled	gram shipery
	November 18, 2016, by and	¹n	a Magaria Walancia
	between Acorda Therapeutics,		Jensting a general
	Inc. and Patheon, Inc.		dataca a minimum terminal
279.	Change Order Pursuant to	Patheon Biologics	# (45 459) n n n n
	Section 9 of the Development	(NJ) LLC	Arrosch Arrosch in
	and Manufacturing Services		1 = 190 _
	Agreement, dated as of June		mil I i i i i i
	18, 2015, by and between		risms i
	Acorda Therapeutics, Inc. and		M 1 1 1111
	Patheon Biologics (NJ) LLC	el l'assurption de l'	r truth griting for the control of t
280.	Manufacturing Service	Patheon Inc.	- share at
	Agreement, dated as of		an and the contract
	September 30, 2010, by and		and galacter to
	between Acorda Therapeutics,		221 11 11 11 11 11 11
	Inc. and Patheon Inc.		marsil consu
281.	Master Agreement for	Patheon Inc.	-
	Pharmaceutical Development	Blacks, 2 shalls,	Alb it you to it
	Services, dated as of		
	September 22, 2011, by and	(*)	
	between Acorda Therapeutics,	Lincoln	Micropolity of the second
	Inc. and Patheon Inc.		M. Wicerson
282.	Change Order Pursuant to	Patheon Biologics	# Proposition of the second
	Section 9 of the Development	(NJ) LLC	
	and Manufacturing Services		1 C 4 1933 L 101 - 101 1
	Agreement, dated as of	0.00	a second for the second
	September 14, 2015, by and		Marine Transco
	between Acorda Therapeutics,		
	Inc. and Patheon Biologics	Petro a data, e p Iran	Other treet or
	(NJ) LLC		Mary Tallian Santa
283.	Fampridine Tablets (10mg,	Patheon Inc.	-1 - 1 - 1
	15mg, 20mg, 25mg) Technical		The state of the s
	Transfer Program Proposal for	galacia grade i	50 of 95
	Commercial Registration,	Mr. Lander	5,7 08,007
	Proposal No. ELN-FQ-0001-		m's m'
	1002-R4, dated as of February		
	26, 2003, by and between		RES-MIC I
	Patheon, Inc. and Acorda		a need from the
201	Therapeutics, Inc.		
284.	Proposal SC_AA1_09032016-	Patheon Biologics	Est Scate of the second
	01 Additional Upstream	(NJ) LLC	M = 02 = 17

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Process Development, dated as of August 26, 2016, by and		
	between Patheon Biologics		
	(NJ) LLC and Acorda		
	Therapeutics, Inc.		
285.	Fampridine-SR Tablets:	Patheon Inc.	-
	Validation Services Pricing		
:	Proposal and Terms and		
	Conditions, Proposal #: 1707-		
	FTR1-0400-0509-R0, dated as of September 14, 2009, by and		
	between Patheon Inc. and		
	Acorda Therapeutics, Inc.		
286.	Ampyra 10 mg ER Tablets	Patheon Inc.	-
	2012 Annual Stability Studies,		
	Proposal #: ACD-CTR1-05-		
	0413-R0, dated as of June 17,		
	2013, by and between Patheon		
	Inc. and Acorda Therapeutics,		
005	Inc.	D 4	
287.	Ampyra 10 mg ER Tablets	Patheon Inc.	-
	2013 Annual Stability Studies – Lot MBZN made with 4-AP		
	(Lot 234-35-2), Proposal #:		
	ACD-CTR1-06-0513-R0,		
	dated as of June 17, 2013, by		
	and between Patheon Inc. and		
	Acorda Therapeutics, Inc.		
288.	Ampyra 10 mg ER Tables,	Patheon Inc.	-
	2015 Annual Stability Studies,		
	Proposal #: ACD-CTR1-13-		
	0615-R0, dated as of July 20,		
	2015, by and between Patheon		
	Inc. and Acorda Therapeutics, Inc.		
289.	Quality Agreement	Patheon Inc.	-
	Commercial Product, dated as	1 2010011 11101	
	of September 30, 2010, by and		
	between Acorda Therapeutics,		
	Inc. and Patheon Inc.		
290.	Manufacturing and Supply	SMC Ltd.	-
	Agreement, dated as of January		
	16, 2020, by and between		
	Acorda Therapeutics, Inc. and		
	SMC Ltd.		

No.	Contract	Counter Party(s)	Cure Amount (\$)
291.	Amendment #1 to Manufacturing and Supply Agreement, dated as of March 31, 2020, by and between SMC, Ltd. and Acorda Therapeutics, Inc.	SMC, Ltd.	Entermode for the control of the con
292.	Quality Agreement, dated as of June 2, 2021, by and between Acorda Therapeutics, Inc. and SMC Ltd.	SMC Ltd.	
293.	Amendment #1 to Master Services Agreement, dated as of September 29, 2015, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	
294.	Amendment #2 to Master Services Agreement, dated as of October 25, 2018, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	
295.	Amendment #3 to Master Services Agreement, dated as of November 10, 2020, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	- 1 Ca all La Ca Segul de Brago a la Ca ca de Brago Call III a para 1 ca a ca a a Call Espain II agrant a la ca
296.	Quality Agreement, dated as of January 22, 2019, by and between Acorda Therapeutics, Inc. and the Hibbert Company Inc. d/b/a the Hibbert Group	The Hibbert Company Inc. d/b/a the Hibbert Group	-32 / Capara and a company of the co
297.	Master Service Agreement, dated as of September 18, 2014, by and between Acorda Therapeutics, Inc. and the Hibbert Company Inc. d/b/a the Hibbert Group	Hibbert Company Inc. d/b/a the Hibbert Group	\$25,848.70
298.	Amendment #4 to Master Services Agreement, dated as of January 31, 2024, by and between the Hibbert Company Inc. and Acorda Therapeutics, Inc.	The Hibbert Group	
299.	Quality Agreement, dated as of October 12, 2021, by and	The Hibbert Group	- 72196 () () () () () () () () () (

No.	Contract	Counter Party(s)	Cure Amount (\$)
1101	between The Hibbert Group	004110111111111111111111111111111111111	Care ramount (b)
	and Acorda Therapeutics, Inc.		
300.	Quality Agreement, dated as of May 10, 2022, by and among Esteve Pharmaceuticals S.A., Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals S.A. Esteve Pharmaceuticals GmbH	-
301.	SC_AA1_09032016-01 Additional Upstream Process Development, dated as of August 26, 2016, by and between Patheon Biologics (NJ) LLC and Acorda Therapeutics, Inc.	Patheon Biologics (NJ) LLC	-
302.	Master Services Agreement, dated as of August 1, 2017, by and between Radius Product Development, Inc. and Acorda Therapeutics, Inc.	Radius Product Development, Inc.	_
303.	Amendment #1 to Master Services Agreement, dated as of July 26, 2019, by and between Radius Product Development, Inc. and Acorda Therapeutics, Inc.	Radius Product Development, Inc.	-
304.	Termination Letter, dated as of January 8, 2024, by and between Acorda Therapeutics, Inc. and Biogen International GMBH	Biogen International GMBH	-
305.	Transaction Document Form # M-4297, undated, by and between International Business Machines Corporation and Acorda Therapeutics, Inc.	International Business Machines Corporation	-
306.	Cloud Services Agreement, undated, by and between International Business Machines Corporation and Acorda Therapeutics, Inc.	International Business Machines Corporation	-
307.	Project Addendum #12, dated as of January 1, 2023, by and between Roadmap	Roadmap Technologies, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Technologies, Inc. and Acorda		
	Therapeutics, Inc.		
308.	Project Addendum #13, dated	Roadmap	-
	as of January 1, 2023, by and	Technologies, Inc.	
	between Roadmap	_	
	Technologies, Inc. and Acorda		
	Therapeutics, Inc.		
309.	Master Service Agreement,	Roadmap	-
	dated as of April 29, 2014, by	Technologies, Inc.	
	and between Acorda	_	
	Therapeutics, Inc. and		
	Roadmap Technologies, Inc.		
310.	Project Addendum #14, dated	Roadmap	-
	as of January 1, 2024, by and	Technologies, Inc.	
	between Roadmap	_	
	Technologies, Inc. and Acorda		
	Therapeutics, Inc.		
311.	Project Addendum #15, dated	Roadmap	-
	as of January 1, 2024, by and	Technologies, Inc.	
Į	between Roadmap		
	Technologies, Inc. and Acorda		
	Therapeutics, Inc.		
312.	Cooperation Agreement, dated	ACS	-
	as of May 10, 2022, by and	PharmaProtect	
	between Acorda Therapeutics	GmBH	
	Ireland Limited and ACS		
212	PharmaProtect GmBH		
313.	Quality Agreement, dated as of	Adoh B.V.	 -
	August 1, 2022, by and		
	between Acorda Therapeutics		
214	Ireland Limited and Adoh B.V.	A 1 1 D 77	
314.	General Service Agreement,	Adoh B.V.	-
	dated as of October 16, 2018,		
	by and between Acorda There a visited		
	Therapeutics Ireland Limited and Adoh B.V.		
315.	Framework Agreement, dated	Sistema Españal da	
313.		Sistema Español de	-
	as of March 3, 2023, by and between Ron Cohen in	Verificacion de	
	representation of Acorda	Medicamentos, S.L.	
	Therapeutics Ireland Limited	J.L.	
	and Sistema Español de		
	Verificacion de Medicamentos,		
	S.L.		

No.	Contract	Counter Party(s)	Cure Amount (\$)
316.	Safety Agreement, dated as of	Adoh B.V.	- Curc Amount (5)
310.	June 2, 2020, by and between	Addir B. V.	
	Acorda Therapeutics Ireland		
	Limited and Adoh B.V.		
317.	Order Form, dated as of	Klick Inc.	-
ļ	December 1, 2018, by and		
	between Acorda Therapeutics,		
	Inc. and Klick Inc.		
318.	Order / Quote (Number: Q-	Bigtincan Mobile	-
	28352), dated as of August 11,	Pty Ltd	
	2023, from Acorda		
	Therapeutics, Inc. to Bigtincan		
 	Mobile Pty Ltd		
319.	Omnicia Agreement, dated as	Omnicia, Inc.	-
	of May 19, 2020, by and		
	between Acorda Therapeutics,		
220	Inc. and Omnicia, Inc.	A 11 - D . T T C	
320.	Confidential Disclosure	Apollo Rx LLC	-
	Agreement, dated as of January		
	26, 2023, by and between		
l	Acorda Therapeutics, Inc. and Apollo Rx LLC		
321.	Project Addendum #1 to the	Apollo Rx LLC	_
321.	Master Services Agreement,	Apollo KA LLC	
	dated as of February 1, 2023,		
	by and between Acorda		
	Therapeutics, Inc. and Apollo		
l	Rx LLC		
322.	Master Services Agreement,	Apollo Rx LLC	\$70,000.00
	dated as of February 1, 2023,	•	
	by and between Acorda		
	Therapeutics, Inc. and Apollo		
	Rx LLC		
323.	Agreement for Authorised	Donawa	-
	Representative Services, dated	Lifescience	
	as of August 22, 2022, by and		
	between Acorda Therapeutics,		
20.1	Inc. and Donawa Lifescience	611	
324.	Master Services Agreement,	Clinipace, Inc.	-
	dated as of October 30, 2018,	d/b/a Caidya	
	by and between Acorda		
	Therapeutics, Inc. and		
325.	Clinipace, Inc. d/b/a Caidya Contract, dated as of March 1,	BSI Group The	_
J2J.	2023, by and between Acorda	Netherlands B.V.	
	1 2023, by and between Acolda	Tremenands D. V.	

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and BSI Group The Netherlands B.V.	V EI dold 17 loves	terbile medical services of the services of th
326.	Master Consulting Agreement, dated as of August 19, 2021, by and between Acorda Therapeutics, Inc. and Gilani, LLC	Gilani, LLC	
327.	Letter Agreement, dated as of April 14, 2021, by and between iPharma Labs, Inc. and Acorda Therapeutics, Inc.	iPharma Labs, Inc.	English to the Design of the Control
328.	Change Order No. 2 to the Original SOW, dated as of January 11, 2024, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	
329.	Change Order No. 1 to the Original SOW, dated as of October 19, 2022, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	
330.	Engagement Letter, dated as of January 7, 2021, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	ELECTRICAL COLLEGE
331.	Mutual Nondisclosure Agreement, dated as of November 8, 2012, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	
332.	Model N Business Services Statement of Work for Acorda Therapeutics, Inc., dated as of December 20, 2021, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	
333.	Co-Operation Agreement, dated as of March 25, 2024, by and among Acorda Therapeutics, Inc., RubiePharm Arzneimittel GmbH, Pharma Consulting Group, S.A. and Biopas Mexico, S.A. de C.V.	RubiePharm Arzneimittel GmbH Pharma Consulting Group, S.A. Biopas Mexico, S.A. de C.V.	Entransista de la companya del companya de la companya del companya de la company

No.	Contract	Counter Party(s)	Cure Amount (\$)
334.	Amendment #1 to Project	Dohmen Life	-
	Addendum #1, dated as of June	Science Services,	
	20, 2014, by and between	LLC	
	Acorda Therapeutics, Inc. and		
	Dohmen Life Science Services,		
	LLC		
335.	Amendment #1 to Project	Dohmen Life	-
	Addendum #3, dated as of	Science Services,	
	September 13, 2016, by and	LLC	
	between Acorda Therapeutics,		
	Inc. and Dohmen Life Science		
	Services, LLC as successor-in-		
	interest to the The F. Dohmen		
226	Co.	Dohmen Life	
336.	Amendment #2 to Project	Science Services,	-
	Addendum #3, dated as of November 6, 2018, by and	LLC	
	between Acorda Therapeutics,	LLC	
	Inc. and Dohmen Life Science		
	Services, LLC as successor-in-		
1	interest to the The F. Dohmen		
ľ	Co.		
337.	Amendment #3 to Project	Eversana Life	\$107,604.04
	Addendum #3, dated as of	Science Services,	
	March 28, 2019, by and	LLC (formerly	
	between Acorda Therapeutics,	known as Dohmen	
	Inc. and Eversana Life Science	Life Science	
	Services, LLC (formerly	Services, LLC)	
	known as Dohmen Life		
	Science Services, LLC)		
338.	Assignment and Assumption	The F. Dohmen Co.	-
	Agreement, dated as of June	Dohmen Life	
	20, 2014, by and between The	Science Services,	
	F. Dohmen Co. and Dohmen	LLC	
	Life Science Services, LLC,		
	and consented to by Acorda		
	Therapeutics, Inc.	<u> </u>	
339.	Master Services Agreement,	The F. Dohmen Co.	-
1	dated as of March 22, 2013, by	(d/b/a MedComm	
	and between Acorda	Solutions)	
	Therapeutics, Inc. and The F.		
	Dohmen Co. (d/b/a MedComm		
	Solutions)		

No.	Contract	Counter Party(s)	Cure Amount (\$)
340.	Project Addendum #1, dated as of March 22, 2013, by and between Acorda Therapeutics, Inc. and The F. Dohmen Co. (d/b/a MedComm Solutions)	The F. Dohmen Co. (d/b/a MedComm Solutions)	
341.	Project Addendum #2, dated as of March 3, 2015, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
342.	Project Addendum #3, dated as of January 1, 2016, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
343.	Settlement Agreement, dated as of January 12, 2018, by and between Acorda Therapeutics, Inc. and Micro USA Inc.	Micro USA Inc.	-
344.	Settlement Agreement, dated as of January 12, 2018, by and between Acorda Therapeutics, Inc. and Actavis Laboratories FL, Inc.	Actavis Laboratories FL, Inc.	-
345.	Settlement Agreement, dated as of December 15, 2015, by and between Acorda Therapeutics, Inc. and Aurobindo Pharma USA.	Aurobindo Pharma USA.	-
346.	Settlement Agreement, dated as of February 8, 2017, by and between Acorda Therapeutics, Inc. and Apotex Inc.	Apotex Inc.	-
347.	Settlement Agreement, dated as of August 11, 2016, by and between Acorda Therapeutics, Inc. and Accord Healthcare, Inc.	Accord Healthcare, Inc.	-
348.	Settlement Agreement, dated as of January 15, 2016, by and between Acorda Therapeutics, Inc. and Par Pharmaceuticals Inc.	Par Pharmaceuticals Inc.	-
349.	Settlement Agreement, dated as of July 27, 2018, by and	Mylan Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and Mylan Inc.		
350.	Settlement Agreement, dated as of October 15, 2015, by and between Acorda Therapeutics, Inc. and Sun Pharmaceuticals Industries Limited.	Sun Pharmaceuticals Industries Limited.	-
351.	Inbrija® Ambassador Program Agreement, dated May 17, 2021, by and between Acorda Therapeutics, Inc. and Rachel Weinberger, as amended.	Rachel Weinberger	-
352.	Inbrija® Ambassador Program Agreement, dated September 27, 2019, by and between Acorda Therapeutics, Inc. and Stephanie Cook, as amended	Stephanie Cook	-
353.	Inbrija™ Ambassador Program Agreement, dated November 6, 2019, by and between Acorda Therapeutics, Inc. and John Baumann.	John Baumann	-
354.	Inbrija® Ambassador Program Agreement, dated April 6, 2020, by and between Acorda Therapeutics, Inc. and James Gaddis, as amended.	James Gaddis	-
355.	Inbrija® Ambassador Program Agreement, dated September 6, 2019, by and between Acorda Therapeutics, Inc. and Robert Harmon, as amended.	Robert Harmon	-
356.	INBRIJA™ Ambassador Program Agreement dated September 9, 2019, as amended	Bettina Chavanne	-
357.	INBRIJA® Patient Video Program Agreement dated October 2, 2023	Kay Henry	-
358.	Care Partner Agreement dated October 2, 2023	Charles Henry	-
359.	INBRIJA® Care Partner Program Agreement dated June 3, 2022, as amended	Kristi Gaddis	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
360.	INBRIJA® Care Partner Program Agreement dated June 6, 2022	Bernadette Baumann	-
361.	Authorization to Reproduce Video and Likeness Release dated October 6, 2019 signed by Cecily Harmon	Cecily Harmon	-
362.	Master Consulting Agreement, dated September 12, 2016, by and between Acorda Therapeutics, Inc. and Gary Rafaloff, as amended.	Gary Rafaloff	-
363.	Master Consulting Agreement, dated July 2, 2015, by and between Acorda Therapeutics, Inc. and Peter LeWitt, as amended. Master Consulting Agreement, dated June 1, 2020, by and between Acorda Therapeutics, Inc. and Peter A. LeWitt, MD, as amended.	Peter LeWitt	
364.	Master Consulting Agreement, dated as of January 12, 2021, by and between Acorda Therapeutics, Inc. and Julie Schwartzbard, MD, as amended.	Julie Schwartzbard	-
365.	Master Consulting Agreement, dated as of January 15, 2021, by and between Acorda Therapeutics, Inc. and Jennifer Durphy, as amended.	Jennifer Durphy	\$650.00
366.	Master Consulting Agreement, dated as of September 10, 2020, by and between Acorda Therapeutics, Inc. and Ray Dorsey, MD, as amended.	Ray Dorsey	-
367.	Master Consulting Agreement, dated as of September 10, 2020, by and between Acorda Therapeutics, Inc. and Rajeev Kumar, MD, as amended.	Rajeev Kumar	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
368.	Master Consulting Agreement, dated as of November 25, 2020, by and between Acorda Therapeutics, Inc. and Ronald F. Pfeiffer, as amended.	Ronald Pfeiffer	-
369.	Master Consulting Agreement, dated as of December 3, 2020, by and between Acorda Therapeutics, Inc. and Dr. Salima Brillman, as amended.	Salima Brillman	-
370.	 Letter agreement titled "Re: Letter regarding Services for Presentation for Consumer Programs for Ampyra ("Letter")", dated as of May 11, 2010, by Acorda Therapeutics, Inc. and acknowledged by Susan Zurndorfer. Consulting Agreement, dated as of May 10, 2007, by and between Acorda Therapeutics, Inc. and Susan Zurndorfer. Letter agreement titled "Re: Letter for Services for Photograph ("Letter")", dated as of March 7, 2011, by Acorda Therapeutics, Inc. and acknowledged by Susan Zurndorfer. Master Consulting Agreement, dated as of March 25, 2013, by and between Acorda Therapeutics, Inc. and Susan Zurndorfer, as amended. 	Susan Zurndorfer	

No.	Contract	Counter Party(s)	Cure Amount (\$)
371.		Lisa Green	-
371.	 Parent's or Guardian's Consent, dated as of February 1, 2012, by Lisa Green Letter agreement titled "Re: Letter Agreement for Participation in Patient Testimonials, an Audio News Releases and a Matte Release", dated as of August 17, 2011, by Acorda Therapeutics, Inc. and acknowledged by Lisa Green. Letter agreement titled "Re: Letter Agreement for Participation in Patient Testimonials, an Audio News Releases and a Matte Release", dated as of September 7, 2012, by Acorda Therapeutics, Inc. and acknowledged by Lisa Green. 	Lisa Green	
372.	Non-Healthcare Professional Ambassador Agreement, dated January 1, 2020, by and between Acorda Therapeutics, Inc. and Zarela Martinez, as amended	Zarela Martinez	-
373.	Non-Healthcare Professional Consulting Agreement dated September 5, 2018	Sarah Diaz	-
374.	Non-Healthcare Professional Consulting Agreement dated January 9, 2019	Gustavo Pavon	-
375.	Non-Healthcare Professional Consulting Agreement dated January 9, 2019	Linda Berghoff	

No.	Contract	Counter Party(s)	Cure Amount (\$)
376.	Non-Healthcare Professional	John Pelchat	
ł	Consulting Agreement, dated		
	September 5, 2018, by and		
	between Acorda Therapeutics,		
	Inc. and John Pelchat.		
377.	Non-Healthcare Professional	Jennifer Parkinson	-
	Consulting Agreement, dated		
	September 5, 2018, by and		
	between Acorda Therapeutics,		
	Inc. and Jennifer Parkinson		
378.	Non-Healthcare Professional	Steve Peters	-
	Consulting Agreement, dated		
	September 5, 2018, by and		
	between Acorda Therapeutics,		
	Inc. and Steve Peters.		
379.	Consultant Agreement (Non-	Lynn Hagerbrant	-
	HCP), dated June 1, 2016, by		
	and between Acorda		
	Therapeutics, Inc. and Lynn		
	Hagerbrant, as amended.		
380.	Non-Healthcare Professional	Michael Bergamo	-
	Consulting Agreement, dated		
	February 8, 2018, by and		
	between Acorda Therapeutics,		
381.	Inc. and Michael Bergamo.	Brenda Vanesse	
381.	Congultant Agraement	Brenda vanesse	-
	Consultant Agreement Olon HCD) detect lyne		
	(Non-HCP), dated June 30, 2016, by and		
	between Acorda		
	Therapeutics, Inc. and		
	Brenda Vanesse, as		
1	amended.		
	Non-Healthcare		
	Professional Consulting		
	Agreement, dated June		
ł	21, 2018, by and		
	between Acorda		
	Therapeutics, Inc. and		
	Brenda Vanesse.	-	

No.	Contract	Counter Party(s)	Cure Amount (\$)
382.		Steven DeWitte	-
362.	 Consultant Agreement (Non-HCP), dated June 8, 2016, by and between Acorda Therapeutics, Inc. and Steven DeWitte. Non-Healthcare Professional Consulting Agreement, dated January 16, 2018, by and between Acorda Therapeutics, Inc. and Steven DeWitte. Non-Healthcare Professional Consulting Agreement, dated August 10, 2018, by and between Acorda Therapeutics, Inc. and Steven DeWitte. 	Steven De witte	
383.	Steven De witte.	Gary Rafaloff	_
	 Patient Consultant Agreement (Non-HCP), dated April 4, 2016, by and between Acorda Therapeutics, Inc. and Gary Rafaloff. Non-Healthcare Professional Consulting Agreement, dated June 21, 2018, by and between Acorda Therapeutics, Inc. and Gary Rafaloff. 		
384.	Healthcare Professional Advisory Board Consulting Agreement, dated as of November 13, 2018, by and between Acorda Therapeutics, Inc. and Rajeev Kumar, MD, FRCPC, as amended.	Rajeev Kumar	-

24-22284-dsj Doc 147 Filed 05/06/24 Entered 05/10/24 13:11:51 Main Document Pg 57 of 57

No.	Contract	Counter Party(s)	Cure Amount (\$)
385.	GI Dysfunction in Patients	Ronald Pfeiffer	-
ł	with Parkinson's Disease Video		
	Consulting, dated as of May		
	13, 2019, by and between		
	Acorda Therapeutics, Inc. and		
	Ronald F. Pfeiffer, MD, as		
	amended.		